Aion Therapeutic Announces Intellectual Property Sale and Management and Board Changes
Aion Therapeutic Announces Intellectual Property Sale and Management and Board Changes
Toronto, Ontario--(Newsfile Corp. - June 30, 2022) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has sold four patent applications and all associated supporting data to Apollon Formularies PLC ("Apollon"), a UK based international pharmaceutical company listed for trading on the Aquis Stock Exchange. Furthermore, Dr. Stephen D. Barnhill has resigned as a Director of Aion Therapeutic and Dr. Herbert Fritsche has resigned as Chief Science Officer of Aion Therapeutic.
安大略省多伦多-(Newsfile Corp.-2022年6月30日)-Aion治疗公司(CSE：AION) ("Aion治疗“或”公司“)今天宣布，已向Apollon Formary PLC出售了四项专利申请和所有相关的支持数据(”阿波龙)，一家在Aquis证券交易所上市的英国国际制药公司。此外，史蒂芬·D·巴恩希尔博士已经辞去艾昂治疗公司首席科学官一职，赫伯特·弗里策尔博士已经辞去艾昂治疗公司首席科学官一职。
Under the terms of an asset purchase agreement (the "APA"), the Company has sold four patent applications, and all associated supporting data to Apollon (collectively, the "Intellectual Property") as detailed below:
根据资产购买协议的条款(“APA)，公司已向Apollon出售了四项专利申请和所有相关的支持数据(合计为知识产权“)详情如下：
- Compositions and Methods for Treatment of Cancers;
- Compositions and Methods for Treatment of Inflammation;
- Methods for Treatment of Human Cancers Using Mushroom Compositions; and
- Methods for Treatment of Human Cancers Using Cannabis Compositions.
- 治疗癌症的组合物和方法；
- 治疗炎症的组合物和方法；
- 使用蘑菇组合物治疗人类癌症的方法；以及
- 使用大麻组合物治疗人类癌症的方法。
In consideration for the Intellectual Property, Apollon has (i) issued to Aion Therapeutic an aggregate of 4,348,679 common shares of Apollon at a deemed price of £0.066 per share; and (ii) agreed to pay to Aion Therapeutic an indefinite royalty fee of 4% of the global net revenue generated by the Intellectual Property (the "Royalty"). The Royalty is payable quarterly in arrears, commencing upon the first commercial product sales utilizing the Intellectual Property.
作为知识产权的代价，Apollon已(I)按每股0.066 GB的价格向Aion治疗公司发行了总计4,348,679股Apollon普通股；以及(Ii)同意向Aion治疗公司支付相当于该知识产权产生的全球净收入4%的无限期使用费。版税“)。特许权使用费从第一次使用知识产权的商业产品销售开始，每季度支付一次。
The Company has retained the following patent applications:
公司保留了以下专利申请：
- Compositions and Methods for Treatment of Psychoses and Psychotic Disorders;
- Compositions and Methods for Promoting Weight Loss and for Treatment of Obesity;
- Antiviral Compositions and Methods for Their Use;
- Compositions For Treatment of Interstitial Cystitis and Other Bladder Disease;
- Cannabis Compositions and Emulsions; and
- Cannabis Compositions and Nanoemulsions.
- 治疗精神病和精神障碍的组合物和方法；
- 促进减肥和治疗肥胖的组合物和方法；
- 抗病毒组合物及其使用方法；
- 治疗间质性膀胱炎和其他膀胱疾病的组合物；
- 大麻组合物和乳剂；以及
- 大麻组合物和纳米乳剂。
Graham Simmonds, Chief Executive Officer of Aion Therapeutic, stated, "The Company has sold its intellectual property to Apollon associated with the treatment of cancer and inflammation which will allow Aion Therapeutic to focus on product development and intellectual property development related to a range of innovative plant-based wellness products including cannabinoids and functional mushrooms in Jamaica and North America. Aion Therapeutic also continues to be a long-term believer in the potential of psilocybin mushrooms and other psychedelic ingredients in the areas of mental health and wellness treatments and will leverage the regulatory landscape and its presence in Jamaica to drive forward operation of Aion International Center for Psychedelic Psychiatry."
Aion治疗公司首席执行官格雷厄姆·西蒙兹表示：“公司已将其与癌症和炎症治疗相关的知识产权出售给Apollon，这将使Aion治疗公司能够专注于产品开发和与牙买加和北美的一系列创新植物保健产品相关的知识产权开发，包括大麻素和功能性蘑菇。Aion治疗公司还继续长期相信裸盖菇素蘑菇和其他迷幻成分在心理健康和健康治疗领域的潜力，并将利用监管格局和其在牙买加的存在来推动Aion国际迷幻精神病学中心的运营。”
This repositioning of the Company's assets will provide for a more streamlined approach to the commercialization of functional wellness-based products and treatments while still having shareholders benefiting through Royalties and stock ownership from Apollon's focus on the treatment of cancer and inflammation.
该公司资产的重新定位将为基于功能健康的产品和治疗的商业化提供一种更精简的方法，同时仍使股东从阿波隆专注于癌症和炎症治疗的特许权使用费和股票所有权中受益。
The APA was unanimously approved by all disinterested directors of the Company. Dr. Barnhill is the Chairman and Chief Executive Officer of Apollon and abstained from voting to approve the APA.
APA获得本公司所有无利害关系董事的一致通过。巴恩希尔博士是Apollon的董事长兼首席执行官，他对批准《行政程序法》投了弃权票。
Furthermore, the Company announced that Dr. Stephen D. Barnhill has resigned as a Director of Aion Therapeutic and from all subsidiary level appointments, and Dr. Herbert Fritsche has resigned as Chief Science Officer of Aion Therapeutic, with both resignations effective June 30, 2022. The Company would like to thank Dr. Barnhill and Dr. Fritsche for their respective contributions and wish them success in their future endeavors.
此外，公司还宣布，斯蒂芬·D·巴恩希尔博士已辞去怡安治疗公司首席科学官一职，赫伯特·弗里策尔博士已辞去怡安治疗公司首席科学官一职，两人的辞职均将于2022年6月30日生效。本公司感谢巴恩希尔博士和弗里切尔博士分别作出的贡献，并祝愿他们在未来的工作中取得成功。
In connection with Dr. Barnhill's resignation, Aion Therapeutic has issued an aggregate of 5,500,000 common shares of the Company at a deemed price of $0.05 per share to settle all amounts owing by Aion Therapeutic and its subsidiaries to Dr. Barnhill (the "Settlement Transaction"). The common shares issued to Dr. Barnhill are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation, and such further restrictions as apply under foreign securities laws.
关于巴恩希尔博士的辞职，Aion治疗公司已按每股0.05美元的价格发行了总计5,500,000股公司普通股，以清偿Aion治疗公司及其子公司欠巴恩希尔博士的所有金额。结算交易根据适用的证券法，向巴恩希尔博士发行的普通股的法定持有期为四个月加自发行之日起计的一天，根据外国证券法适用的此类进一步限制。
The Settlement Transaction constituted a "related party transaction" as defined in Multilateral Instrument 61-101 - Protection of Minority Securityholders in Special Transactions ("MI 61-101"), as Dr. Barnhill was a director of Aion Therapeutic at the time of the Settlement Transaction and acquired an aggregate of 5,500,000 common shares of the Company. The Company is relying on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a), respectively, of MI 61-101, as the fair market value of the common shares issued to Dr. Barnhill does not exceed 25% of the market capitalization of the Company, as determined in accordance with MI 61-101. The Company did not file a material change report in respect of the related party transaction at least 21 days before the closing of the transaction, which the Company deems reasonable in order to complete the Settlement Transaction in an expeditious manner. The Settlement Transaction was unanimously approved by all disinterested directors of the Company.
结算交易构成多边文书61-101所界定的“关联方交易”--特殊交易中少数股证券持有人的保护 ("米其林61-101“)，因为在结算交易发生时，巴恩希尔博士是怡安治疗公司的董事成员，并收购了总计5,500,000股本公司的普通股。本公司依据MI 61-101第5.5(A)及5.7(1)(A)节分别载于MI 61-101的估值及少数股东批准规定的豁免，因为根据MI 61-101厘定，向巴恩希尔博士发行的普通股的公平市值不超过本公司市值的25%。本公司并无于交易结束前至少21天提交有关关联方交易的重大变动报告，本公司认为此举是合理的，以便迅速完成结算交易。和解交易获得本公司全体无利害关系董事的一致通过。
About Aion Therapeutic Inc.
Aion治疗公司简介
Aion Therapeutic Inc. through its wholly-owned subsidiary, AI Pharmaceuticals Jamaica Limited, is in the business of research and development, treatment, data mining and state-of-the-art artificial intelligence (machine learning) techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals utilizing compounds from cannabis (cannabinoids), psychedelic mushrooms (psilocybin), fungi (edible mushroom), natural psychedelic formulations (Ayahuasca), and other medicinal plants in a legal environment for this type of discovery. In addition, Aion Therapeutic is creating a strong international intellectual property portfolio related to its discoveries.
Aion治疗公司通过其全资子公司AI PharmPharmticals牙买加有限公司从事研发、治疗、数据挖掘和最先进的人工智能(机器学习)技术业务，专注于在合法环境下开发组合药品、营养食品和化妆品，利用大麻(大麻)、迷幻蘑菇(裸盖菇素)、真菌(食用菌)、天然迷幻制剂(Ayahuasca)和其他药用植物的化合物进行此类发现。此外，Aion治疗公司正在创建与其发现相关的强大的国际知识产权组合。
For further information, please contact:
如需更多信息，请联系：
Aion Therapeutic Inc.
Graham Simmonds
Executive Vice Chair & CEO
(416) 843-2881
Aion治疗公司
格雷厄姆·西蒙兹
执行副主席兼首席执行官
(416) 843-2881
DISCLAIMER & READER ADVISORY
免责声明和读者建议
Certain information set forth in this news release may contain forward-looking information that involve substantial known and unknown risks and uncertainties. This forward-looking information is subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, the impact of general economic conditions, industry conditions, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking information. The parties undertake no obligation to update forward-looking information except as otherwise may be required by applicable securities law.
本新闻稿中陈述的某些信息可能包含前瞻性信息，这些信息涉及大量已知和未知的风险和不确定性。这些前瞻性信息受到许多风险和不确定性的影响，其中某些风险和不确定性不是公司所能控制的，包括但不限于一般经济条件、行业条件和对监管批准的依赖的影响。请读者注意，编制这类信息时使用的假设虽然在编制时被认为是合理的，但可能被证明是不准确的，因此不应过度依赖前瞻性信息。双方不承担更新前瞻性信息的义务，除非适用的证券法另有要求。
To view the source version of this press release, please visit
要查看本新闻稿的源版本，请访问
译文内容由第三方软件翻译。